| Editor’s Note: The Fierce PM Tracker will not publish Monday, Feb. 17, in observance of Presidents Day. We’ll be back in your inbox on Tuesday, Feb. 18. |
|
Wednesday, February 26, 2025 | 12pm ET / 9am PT In today’s world, life sciences and healthcare companies face major challenges — managing complex datasets, accelerating drug discovery, and advancing precision research. Register for our webinar to learn how to overcome overcome these challenges using AI cloud infrastructure and advanced machine learning tools.
|
|
Today’s Big NewsFeb 14, 2025 |
| By Kevin Dunleavy Bristol Myers Squibb is striking out in its attempts to broaden the label of its first-in-class combo drug Opdualag. On Thursday, the company revealed that a phase 3 trial of Opdualag as an adjuvant treatment for patients with completely resected state III and stage IV melanoma did not achieve its primary endpoint. |
|
|
|
By James Waldron A trial of Moderna’s norovirus vaccine in the U.S. has been put on hold by the FDA over a reported case of neurological disorder. |
By Fraiser Kansteiner In 2024’s fourth quarter, Moderna’s cost of sales came out to $739 million, which included a major $238 million charge tied to the cancellation of a contract manufacturing agreement toward the end of the year. |
By Noah Tong The federal government is laying off thousands of health agency workers and others this week. Here's what we know so far. |
|
Thursday, February 27, 2025 | 2pm ET / 11am PT The quest to discover biomarkers for therapeutic response through traditional genomic sequencing and other omic approaches has yet to deliver clinically actionable tools for most patients. Don’t miss this compelling discussion on how cutting-edge glycoproteomic technologies are unlocking new clinical insights.
|
|
By Gabrielle Masson Boston biotech Kojin Therapeutics is closing its doors, citing four funding challenges and a few valuable lessons learned. |
By Nick Paul Taylor UCB’s Bimzelx is firmly on physicians’ radars, with Spherix Global Insights finding that awareness of the drug was tracking ahead of AbbVie’s Rinvoq and Skyrizi three months into its psoriatic arthritis launch. Yet, the analysis suggests UCB has work to do to turn awareness into uptake. |
By Conor Hale The company’s randomized clinical trial, published in Nature Medicine, tested the addition of AI-targeted heart ablations to conventional pulmonary vein isolation. |
By James Waldron Two months after Allogene abandoned plans for its CAR-T in leukemia, analysts have suggested that fresh phase 1 data in lymphoma show the therapy can “leapfrog” the competition. |
By Fraiser Kansteiner,Eric Sagonowsky,Angus Liu,Zoey Becker,Kevin Dunleavy In this tracker, Fierce Pharma is recording the regulatory progress of in-market products, including expansions into key geographies and new indications. Some of these updates may not meet the bar for standalone stories, but we think they are still worth mentioning. |
By Darren Incorvaia,Zoey Becker After its depression candidate failed a phase 3 trial and disappointed analysts, Neumora is shaking up its leadership team. President and CEO Henry Gosebruch is leaving the company effective Feb. 14, and will be replaced as CEO by co-founder Paul Berns and as president by Joshua Pinto, Ph.D. |
By Nick Paul Taylor Otsuka has broken up with a clutch of clinical cancer candidates. The Japanese drugmaker said strategic reasons—the pharma equivalent of “it’s not you, it’s me”—underpinned the decision to ax the assets. |
By Andrea Park A group of former leaders from health comms giant Inizio Evoke have come together to launch Flex Marketing, a new agency catering to pharmaceutical, biotech, medtech and health tech clients. |
By Gabrielle Masson Bambusa Therapeutics has raised about $90 million to build out a pipeline of next-gen bispecific antibodies targeting immunological and inflammatory (I&I) conditions. |
Fierce podcastsDon’t miss an episode |
| | This week on "The Top Line," we celebrate Valentine's Day with a discussion about heart-related updates and the stories we've loved covering so far this year. |
|
|---|
|
|
|
Tuesday, February 25, 2025 | 2pm ET / 11am PT Discover how a direct-to-individual approach to real-world data (RWD) is transforming obesity treatment insights. Learn how the right engagement strategies enable effective tracking of GLP-1 use, adherence, and outcomes, leveraging wearable and multi-modal data for predictive modeling and early interventions. Join us to explore new ways to enhance patient understanding. Register now.
|
|
| WhitepaperThis paper reviews key developments in the oncology market during 2024 and outlines what they mean for the future. Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
